Robert L Coleman
Overview
Explore the profile of Robert L Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
454
Citations
15933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim M, Glassman D, Handley K, Lankenau Ahumada A, Jennings N, Bayraktar E, et al.
Cancer Med
. 2024 Aug;
13(15):e70031.
PMID: 39114948
Background: GP-2250, a novel analog of taurultam (TRLT), has emerged as a potent anti-neoplastic drug; however, the mechanisms underlying its effects are not well understood. Here, we investigated the mechanism...
12.
Nemunaitis J, Stanbery L, Walter A, Wallraven G, Nemunaitis A, Horvath S, et al.
Future Oncol
. 2024 Aug;
20(29):2149-2164.
PMID: 39101448
We describe in this review the historical evidence leading up to the concept and design of Vigil and subsequent clinical applications including safety and efficacy in a randomized, controlled Phase...
13.
Mirza M, Chase D, Slomovitz B, Christensen R, Novak Z, Black D, et al.
Future Oncol
. 2024 Jul;
21(2):151-168.
PMID: 38990090
No abstract available.
14.
Monk B, Tewari K, Randall L, Pothuri B, Slomovitz B, Coleman R, et al.
Gynecol Oncol
. 2024 Jun;
188:81-82.
PMID: 38936284
No abstract available.
15.
Coleman R, Lorusso D, Oaknin A, Cecere S, Denys H, Colombo N, et al.
Int J Gynecol Cancer
. 2024 Jun;
34(8):1119-1125.
PMID: 38858103
Objective: The single-arm, phase II SORAYA trial (NCT04296890) of mirvetuximab soravtansine-gynx in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer (n=105 (efficacy-evaluable)) met its primary endpoint with an objective response rate...
16.
Chan J, Tewari K, Monk B, Herzog T, Coleman R, Richardson M, et al.
Gynecol Oncol
. 2024 Jun;
187:249-252.
PMID: 38838439
No abstract available.
17.
Sfeir S, Allen L, Algera M, Morton R, Farrell R, Brennan D, et al.
Int J Gynecol Cancer
. 2024 May;
34(9):1408-1415.
PMID: 38821547
Objective: To explore the barriers to ovarian cancer care, as reported in the open ended responses of a global expert opinion survey, highlighting areas for improvement in global ovarian cancer...
18.
Pitiyarachchi O, Ansell P, Coleman R, Dinh M, Holman L, Leath 3rd C, et al.
Gynecol Oncol
. 2024 May;
187:221-226.
PMID: 38821039
Objective: Due to limited data on homologous recombination deficiency (HRD) in older patients (≥ 70 years) with advanced stage high grade serous ovarian cancer (HGSC), we aimed to determine the...
19.
Ramirez P, Robledo K, Frumovitz M, Pareja R, Ribeiro R, Lopez A, et al.
J Clin Oncol
. 2024 May;
42(23):2741-2746.
PMID: 38810208
JCO The aim of this study was to compare overall survival between open and minimally invasive radical hysterectomy with participants followed for 4.5 years. The primary objective was to evaluate...
20.
Vergote I, Perez Fidalgo A, Valabrega G, Monk B, Herzog T, Cibula D, et al.
Int J Gynecol Cancer
. 2024 Apr;
34(8):1283-1289.
PMID: 38627035
Background: Patients with advanced/recurrent endometrial cancer have a poor prognosis and limited treatment options. Biomarkers such as tumor protein 53 () in endometrial cancer can integrate novel strategies for improved...